Bispecific Ab Retinopathy/Cancer

Our TIME2 trial with subcutaneous AKB-9778 was the first to show the promise of combining Tie2 activation and VEGF inhibition in patients with diabetic macular edema (DME). Based on TIME2 and promising preclinical data, intravitreal ARP-1536, Aerpio’s therapeutic antibody, is in preclinical development as an adjunct to anti-VEGF therapy for DME and wet age-related macular degeneration (wAMD).

Combining Tie2 activation and VEGF inhibition is also a promising approach to treating cancer via enhanced vascular normalizing effects that may limit tumor spread and improve the anti-tumor activity of conventional cancer treatments including chemotherapy, radiation therapy and immunotherapy.

Based on these concepts Aerpio’s bispecific biologic, combining the Tie2 activating properties of ARP-1536 with VEGF neutralization is in early preclinical development for DME and wAMD by intravitreal administration and for cancer by systemic (intravenous or subcutaneous) administration.